Lantheus (Nasdaq:LNTH) announced that it acquired Cerveau Technologies, a developer of a positron emission tomography imaging agent for detecting Alzheimer’s disease. Cerveau develops the MK-6240 second-generation F 18-labeled PET imaging agent. It targets Tau tangles in Alzheimer’s disease. Bedford, Massachusetts–based Lantheus intends to pay an upfront payment and potential development and commercial milestone payments. It […]
Cerveau Technologies
Cerveau inks licensing deal with AbbVie for tau imaging agent
Cerveau Technologies has inked a deal to license and supply AbbVie (NYSE:ABBV) with its [F-18]MK-6240 investigational tau imaging agent, the company said today. After the FDA cleared the investigational new drug application for Cerveau’s imaging agent in June, the company said it planned to work with pharmaceutical partners to evaluate the product’s use in positron emission tomography scans to assess […]
FDA clears IND for Cerveau’s tau imaging agent
Cerveau Technologies said today that the FDA cleared the investigational new drug application for its tau imaging agent. The company plans to work with pharmaceutical partners to evaluate the product’s use in positron emission tomography scans to assess neurofibrillary tangles in the brain. NFTs composed of aggregated tau protein are characteristic of certain neurodegenerative conditions like […]
Cerveau Technologies, Wisconsin Alzheimer’s Center ink research deal
Cerveau Technologies said today that it landed a clinical research agreement with the University of Wisconsin-Madison Alzheimer’s Research Center to study an early stage imaging agent with positron emission tomography scans to assess the statusand progression of neurofibrillary tangles in the brain. Neurofibrillary tangles composed of tau protein are characteristic of certain neurodegenerative diseases, such […]